Ligand Pharmaceuticals | LGND - Pre Tax Profit


Ligand Pharmaceuticals reported $56.78M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Agenus USD -10.61M 263.52M Dec/2025
Amgen USD 1.51B 2.41B Dec/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
Baxter International USD -756M 877M Dec/2025
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Enviri Corporation USD 233.18M 21.88M Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Glaxosmithkline GBP 2.46B 569M Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -162.1M 164.84M Mar/2026
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Ligand Pharmaceuticals USD 56.78M 84.36M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Pacira USD 571K 8.95M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Veracyte USD 29.97M 10.66M Mar/2026